Company News
https://chimebiologics.com/wp-content/uploads/2020/03/logo-ch-en-257.png
0
0
chi9iua
https://chimebiologics.com/wp-content/uploads/2020/03/logo-ch-en-257.png
chi9iua2024-04-24 15:37:012024-04-25 15:37:02Agreement of Collecting Personal Information
https://chimebiologics.com/wp-content/uploads/2020/03/logo-ch-en-257.png
0
0
chi9iua
https://chimebiologics.com/wp-content/uploads/2020/03/logo-ch-en-257.png
chi9iua2024-04-24 11:37:322024-04-25 18:01:42Privacy Policy 
https://chimebiologics.com/wp-content/uploads/2024/04/Collaborative-whitepaper.jpg
383
900
chi9iua
https://chimebiologics.com/wp-content/uploads/2020/03/logo-ch-en-257.png
chi9iua2024-04-19 17:46:332024-04-25 11:24:53Whitepaper | Immunogenicity of Innovative and Biosimilar Monoclonal Antibodies
https://chimebiologics.com/wp-content/uploads/2024/04/企业微信截图_17129068437411.png
287
667
chi9iua
https://chimebiologics.com/wp-content/uploads/2020/03/logo-ch-en-257.png
chi9iua2024-04-09 17:24:252024-04-12 17:27:05Mr. Huang Guo, Deputy Commissioner of China NMPA Visits Chime Biologics Wuhan Headquarter
https://chimebiologics.com/wp-content/uploads/2024/03/9767d405-4a42-4920-bf40-d2de7d681a83.png
383
900
Qiqi Zhang
https://chimebiologics.com/wp-content/uploads/2020/03/logo-ch-en-257.png
Qiqi Zhang2024-03-12 16:00:442024-03-11 16:54:36Domain Therapeutics and Chime Biologics announce manufacturing agreement to advance novel anti-CCR8 antibody for cancer immunotherapy
https://chimebiologics.com/wp-content/uploads/2024/03/e649693b-71c1-4252-b41f-e9ca6e8f8432.png
383
900
Qiqi Zhang
https://chimebiologics.com/wp-content/uploads/2020/03/logo-ch-en-257.png
Qiqi Zhang2024-03-07 09:07:362024-03-07 10:01:07Chime Biologics Achieves ISO 27001 Certification to Strengthen Information Security in the CDMO Industry
https://chimebiologics.com/wp-content/uploads/2023/10/582af528-b2ba-4133-83c4-b8b4e8546a3f.jpg
383
900
Qiqi Zhang
https://chimebiologics.com/wp-content/uploads/2020/03/logo-ch-en-257.png
Qiqi Zhang2023-09-28 13:18:512023-11-14 10:02:08Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
https://chimebiologics.com/wp-content/uploads/2023/09/签约图片-final.jpg
1063
1890
Qiqi Zhang
https://chimebiologics.com/wp-content/uploads/2020/03/logo-ch-en-257.png
Qiqi Zhang2023-09-20 09:50:222023-09-25 10:58:18Chime Biologics Enters into a Strategic Cooperation Agreement with Korea Kings Pharm to Accelerate the Biosimilar Launch